Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adolor Corporation
Adolor Regains Rights to Entereg alvimopan for OBD
September 19th, 2008
Adolor Corporation (Nasdaq: ADLR) announced that GlaxoSmithKline (GSK) has returned to Adolor worldwide rights related to Entereg(R) (alvimopan) for chronic opioid bowel dysfunction (OBD). GSK is retaining rights to Entereg for postoperative ileus (POI), and the companies will continue to collaborate on the development and commercialization of Entereg for POI in the United States. Adolor announced in July 2008 that the U. S. Food and Drug Administration (FDA) lifted the clinical hold on the OBD Investigational New Drug Application. "There is a large, unmet need for treatment options for the many patients who suffer with chronic OBD," said Michael R....
Source: Health Business Week (2008-09-19)
|
